Clinical Trial Update: An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial of rivaroxaban in patients with acute coronary syndrome has completed; results outlining efficacy and safety have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Myocardial Ischemia
• Unstable Angina

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Acute Coronary Syndrome, Myocardial Infarction | Phase 3 | Status: COMPLETED | Results posted: 2014-06-02